In this study we analysed by next-generation sequencing (NGS), using a targeted sequencing panel, a cohort of 133 EGFR mutant NSCLC patients, who received first-line therapy with EGFR TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.